Welcome to our dedicated page for VanEck Green Infrastructure ETF news (Ticker: RNEW), a resource for investors and traders seeking the latest updates and insights on VanEck Green Infrastructure ETF stock.
The news associated with the ticker RNEW spans several distinct contexts, reflecting its use by different issuers and in different markets. One set of news comes from VanEck, which announced that the Board of Trustees of VanEck ETF Trust approved the liquidation and dissolution of the VanEck Green Infrastructure ETF, trading under the ticker RNEW on Nasdaq. That announcement details the final trading date on the exchange, the planned delisting of the fund’s shares, and the process by which shareholders would receive a cash liquidating distribution equal to the net asset value of their holdings, along with information about potential final income and capital gains distributions and related tax reporting.
Another stream of RNEW-related news involves Ecofin U.S. Renewables Infrastructure Trust plc, which uses RNEW as its symbol on the London Stock Exchange. Ecofin reported that this trust has been classified as an Article 9 product under the EU Sustainable Finance Disclosure Regulation and that it bears the London Stock Exchange’s Green Economy Mark. This news places RNEW in the context of renewables infrastructure and sustainable investment strategies.
A third category of coverage links RNEW to a proposed business combination between Suneva Medical, Inc. and Viveon Health Acquisition Corp. Press releases describe Suneva as a company in regenerative aesthetics and Viveon Health as a healthcare-focused SPAC, and state that, upon completion of their transaction, the combined company’s securities are expected to trade under the symbol RNEW on the NYSE or NYSE American. These items focus on merger terms, regulatory steps such as the planned filing of a Form S-4 with the SEC, and the strategic rationale for the combination.
Together, these news items show that RNEW-related coverage can include fund liquidations, regulatory classifications for sustainable investment vehicles, and SPAC merger announcements. Readers interested in RNEW can use this page to follow how the ticker has been referenced across these different developments.
Ecofin announced its Ecofin Global Renewables Infrastructure UCITS Fund has been classified as Article 9 under the EU's Sustainable Finance Disclosure Regulation (SFDR), effective December 1, 2022. This designation signifies compliance with the highest sustainability criteria. Ecofin aims for at least 90% of the fund's portfolio to comprise sustainable investments, emphasizing low-carbon power generation and companies transitioning from fossil fuels to renewable energy. The Ecofin U.S. Renewables Infrastructure Trust (RNEW) also meets the Article 9 standards and holds the London Stock Exchange's Green Economy Mark.
Suneva Medical has received Canadian regulatory approval for its Dermapose® all-in-one fat sizing syringe, enhancing its presence in the regenerative aesthetics market. Additionally, the U.S. FDA granted 510(k) clearance for the larger 30 mL Amplifine PRP Gel Tube, allowing for greater efficiency in regenerative treatments. These advancements highlight Suneva's commitment to providing innovative, minimally invasive solutions in aesthetic procedures, catering to the growing demand for natural-looking treatment options.
Suneva Medical announced FDA acceptance of updates to the Plasma IQ label, notably removing the eye contraindication, enhancing treatment options around the eye. This update supports the company’s merger with Viveon Health Acquisition Corp. (VHAQ), aiming for increased market access. Plasma IQ is the first handheld FDA-cleared plasma energy device for skin lesion treatment. The merger is set to allow shares to trade under the symbol RNEW upon completion. Suneva, located in San Diego, continues to innovate in regenerative aesthetics, focusing on patient solutions.
Suneva Medical, an innovative firm in regenerative aesthetics, has announced a merger agreement with Viveon Health Acquisition Corp (NYSE: VHAQ). The merger, expected to close in the first half of 2022, aims to leverage Suneva's patented products to meet the growing demand in the $11 billion regenerative aesthetics market. The pro forma equity valuation of the combined company is projected at $511 million, with potential share earn-outs tied to performance metrics. Both companies emphasize enhancing shareholder value and expanding market reach through this partnership.